Recherche
-
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
(Leukemia, 2020-07-21)Article de revue -
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
(Blood Advances. vol. 5, n° 5, pp. 1442-1451, 2021-03-09)Article de revue -
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
(Blood Cancer Journal. vol. 12, n° 4, pp. 56, 2022-04-08)Article de revueLibre accès -
Clonal haematopoiesis and cardiovascular diseases: A growing relationship
(Archives of cardiovascular diseases, 2021-03-10)Article de revueLibre accès -
Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
(HemaSphere. vol. 4, n° 3, pp. e364, 2020-06)Article de revueLibre accès -
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
(Genes, Chromosomes & Cancer. vol. 62, n° 3, pp. 139-151, 2023-03-01)Article de revue -
Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells
(Blood. vol. 134, n° 26, pp. 2383–2387, 2019-12)Article de revueAccès réservé -
STAT5-and hypoxia-dependent upregulation of AXL
(Haematologica. vol. 104, n° 10, pp. 2017–2027, 2019-10)Article de revueLibre accès -
JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens
(Leukemia & lymphoma. vol. 57, n° 8, pp. 1949–1951, 2016-08)Article de revue -
Clonal hematopoiesis are not associated with an increased systemic inflammation, ATHerosclerosis nor incidence of atherothrombosis: Results from the 3-city study (CHIP-3C)
(Atherosclerosis. vol. 355, pp. 29, 2022-08-01)Article de revueLibre accès